Yang L, Wei X, Gong Y
Cancer Med. 2023; 13(1):e6871.
PMID: 38146893
PMC: 10807681.
DOI: 10.1002/cam4.6871.
Sobieralski P, Wasag B, Leszczynska A, Zuk M, Bieniaszewska M
Front Oncol. 2023; 13:1224590.
PMID: 37671053
PMC: 10475996.
DOI: 10.3389/fonc.2023.1224590.
Ralli S, Jones S, Leach S, Lynch H, Brooks-Wilson A
PLoS One. 2023; 18(6):e0287602.
PMID: 37379307
PMC: 10306212.
DOI: 10.1371/journal.pone.0287602.
Vlasschaert C, Mack T, Heimlich J, Niroula A, Uddin M, Weinstock J
Blood. 2023; 141(18):2214-2223.
PMID: 36652671
PMC: 10273159.
DOI: 10.1182/blood.2022018825.
Gao X, You X, Droin N, Banaszak L, Churpek J, Padron E
Exp Hematol. 2022; 115:14-19.
PMID: 36183966
PMC: 10364143.
DOI: 10.1016/j.exphem.2022.09.003.
Compartment-specific mutational landscape of clonal hematopoiesis.
Hartmann L, Hecker J, Rothenberg-Thurley M, Riviere J, Jentzsch M, Ksienzyk B
Leukemia. 2022; 36(11):2647-2655.
PMID: 36131041
PMC: 9613457.
DOI: 10.1038/s41375-022-01700-3.
Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel.
Tan J, Chow Y, Zainul Abidin N, Chang K, Selvaratnam V, Tumian N
BMC Med Genomics. 2022; 15(1):10.
PMID: 35033063
PMC: 8760696.
DOI: 10.1186/s12920-021-01145-0.
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.
Luque Paz D, Riou J, Verger E, Cassinat B, Chauveau A, Ianotto J
Blood Adv. 2021; 5(5):1442-1451.
PMID: 33666653
PMC: 7948260.
DOI: 10.1182/bloodadvances.2020003444.
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?.
Sanz G, Ibanez M, Such E
Blood Adv. 2019; 3(21):3454-3460.
PMID: 31714959
PMC: 6855105.
DOI: 10.1182/bloodadvances.2019000680.
Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era.
Montes-Moreno S, Routbort M, Lohman E, Barkoh B, Kanagal-Shamanna R, Bueso-Ramos C
PLoS One. 2018; 13(9):e0204218.
PMID: 30222780
PMC: 6141087.
DOI: 10.1371/journal.pone.0204218.
Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.
Alberti M, Nonavinkere Srivatsan S, Shao J, McNulty S, Chang G, Miller C
Leukemia. 2018; 32(8):1874-1878.
PMID: 29959414
PMC: 6402595.
DOI: 10.1038/s41375-018-0193-y.
ASXL1 mutations in Chinese patients with essential thrombocythemia.
Nie Y, Sun M, He C, Ju M, Zhou F, Wu S
Exp Ther Med. 2018; 15(5):4149-4156.
PMID: 29725364
PMC: 5920505.
DOI: 10.3892/etm.2018.5939.
ASXL1 c.1934dup;p.Gly646Trpfs*12-a true somatic alteration requiring a new approach.
Yannakou C, Jones K, McBean M, Thompson E, Ryland G, Doig K
Blood Cancer J. 2017; 7(12):656.
PMID: 29242575
PMC: 5802455.
DOI: 10.1038/s41408-017-0025-8.
ASXL gain-of-function truncation mutants: defective and dysregulated forms of a natural ribosomal frameshifting product?.
Dinan A, Atkins J, Firth A
Biol Direct. 2017; 12(1):24.
PMID: 29037253
PMC: 5644247.
DOI: 10.1186/s13062-017-0195-0.
Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance.
Goldberg L, Gough S, Lee F, Dang C, Walker R, Zhu Y
Genes Chromosomes Cancer. 2017; 56(6):472-483.
PMID: 28196408
PMC: 5399546.
DOI: 10.1002/gcc.22451.
Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.
McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias J, Tischler G
Blood. 2016; 128(1):e1-9.
PMID: 27121471
PMC: 4937362.
DOI: 10.1182/blood-2015-11-683334.
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.
Patnaik M, Tefferi A
Blood Cancer J. 2016; 6:e393.
PMID: 26849014
PMC: 4771968.
DOI: 10.1038/bcj.2016.5.
Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.
Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, Yilmaz C, Nalcaci M, Yavuz A
J Blood Med. 2015; 6:157-75.
PMID: 26082670
PMC: 4459634.
DOI: 10.2147/JBM.S78826.
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia.
Cui Y, Tong H, Du X, Li B, Gale R, Qin T
Exp Hematol Oncol. 2015; 4:14.
PMID: 26019984
PMC: 4445804.
DOI: 10.1186/s40164-015-0009-y.
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.
Patnaik M, Itzykson R, Lasho T, Kosmider O, Finke C, Hanson C
Leukemia. 2014; 28(11):2206-12.
PMID: 24695057
DOI: 10.1038/leu.2014.125.
